Home Online Features GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
Press Releases
GC Cell  
March 12, 2025

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

YONGIN, South Korea, March 12, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social